Brief: Glycomimetics Announces Investigator-Sponsored Phase 2 Clinical Trial Evaluating Uproleselan For Prevention Of Gastro-Intestinal Toxicity In Autologous Hematopoietic Cell Transplantation
26/05/2021 14:25
May 26 (Reuters) - GlycoMimetics Inc GLYC.O :
* GLYCOMIMETICS ANNOUNCES INVESTIGATOR-SPONSORED PHASE 2
CLINICAL
TRIAL EVALUATING UPROLESELAN FOR PREVENTION OF GASTRO-INTESTINAL
TOXICITY IN AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION
* GLYCOMIMETICS INC - CLINICIANS AT WASHINGTON UNIVERSITY IN
ST.
LOUIS ENROLL TRIAL'S FIRST PATIENT AT SITEMAN CANCER CENTER
Source text for Eikon: ID:nBw1TkQPTa
Further company coverage: GLYC.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Crescent Biopharma
See all newsBrief: Crescent Biopharma - Potential To Initiate First CR-001 Phase 3 Study In Early 2028
Brief: Crescent Biopharma Announces FDA Clearance Of Ind Application For CR-002, A Pd-L1-Targeted Topoisomerase Inhibitor Adc, For The Treatment Of Solid Tumors
Crescent Biopharma posts smaller-than-expected Q2 net loss
U.S. STOCKS ON THE MOVE-Cintas, Veradermics
Crescent Biopharma slips on $125 mln share offering